Schrödinger cuts 2025 software growth outlook as Q3 revenue rises 54% to $54.3 million
Schrödinger reported third-quarter 2025 total revenue of $54.3 million, up 54% from a year earlier, and a net loss of $32.8 million, narrower than the $38.1 million loss in the prior-year quarter. The company lowered its full-year 2025 software revenue growth guidance to 8% to 13% from 10% to 15%, and said it expects savings of approximately $70 million from expense-reduction measures and a shift away from independent clinical development.
Key points
- Q3 total revenue was $54.3 million, up 54%; software revenue was $40.9 million, up 28%, and drug discovery revenue was $13.5 million versus $3.4 million a year earlier.
- Full-year 2025 software revenue growth guidance was cut to 8% to 13% from 10% to 15%, while drug discovery revenue guidance was raised to $49 million to $52 million from $45 million to $50 million.
- Q3 net loss was $32.8 million, versus $38.1 million in Q3 2024; non-GAAP net loss was $42.3 million.
- Cash, cash equivalents, restricted cash and marketable securities totaled $401.0 million at September 30, 2025.
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.